TIDMMXCT TIDMTTM
RNS Number : 6449Z
MaxCyte, Inc.
25 May 2021
FOR IMMEDIATE RELEASE
Celularity and MaxCyte Sign Strategic Platform Licence
to Advance Celularity's Off-the-shelf Allogeneic Cellular
Therapy Product Candidates
Celularity to utilize MaxCyte's Flow Electroporation (R)
technology and ExPERT(TM) platform to advance its off-the-shelf
placental-derived allogeneic cellular therapies to treat
hematological malignancies, solid tumours, and infectious and
degenerative diseases
FLORHAM PARK, NJ, and GAITHERSBURG, MD, 25 May 2021 -
Celularity, Inc. ("Celularity"), a clinical-stage biotechnology
company leading the next evolution in cellular medicine with the
development of off-the-shelf allogeneic therapies derived from the
postpartum human placenta, and MaxCyte, Inc., (LSE: MXCT, MXCN), a
leading provider of cell-engineering platform technologies for next
generation cell-based therapies, today announce the signing of a
strategic platform licence.
Celularity will obtain non-exclusive rights to use MaxCyte's
Flow Electroporation(R) technology and ExPERT(TM) platform enabling
Celularity to accelerate the development of innovative, off the
shelf allogeneic cell therapies, including genetically modified
natural killer (NK) cell therapies and CAR T-cell therapies derived
from the postpartum placenta. In return, MaxCyte is entitled to
platform licensing fees and programme-related milestone
payments.
"This strategic relationship provides Celularity with access to
MaxCyte's unique electroporation technology platform, representing
an important enabling step in allogeneic cell therapy. We expect to
leverage this transaction and our new state-of-the-art
manufacturing facility to advance the delivery of best-in-class
cell therapies to patients with unmet medical needs," said Robert
J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive
Officer of Celularity. "We are very excited to be working with
MaxCyte, an established leader in cell engineering."
Doug Doerfler, President & CEO of MaxCyte, said:
"Celularity's approach to developing new immunotherapies to treat
cancer and other diseases appears very promising. The company is
leading the next evolution in cellular medicine by leveraging a
novel cell source, and we are very proud the team has selected
MaxCyte's technology to help enable this important work."
MaxCyte's ExPERT(TM) instrument portfolio represents the next
generation of leading, clinically validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
About Celularity
Celularity , headquartered in Florham Park, N.J., is a clinical
stage biotechnology company leading the next evolution in cellular
medicine by developing off-the-shelf placenta -derived allogeneic
cell therapies, including unmodified NK cells, genetically-modified
NK cells, T cells engineered with a CAR (CAR T-cells), and
mesenchymal-like adherent stromal cells ( ASCs ) targeting
indications across cancer, infectious and degenerative diseases.
Celularity believes that by harnessing the placenta's unique
biology and ready availability, it will be able to develop
therapeutic solutions that address significant unmet global needs
for effective, accessible, and affordable therapies.
In January 2021, Celularity entered into a definitive merger
agreement with GX Acquisition Corp. ("GX") to create a publicly
listed leader in allogeneic cellular therapy. GX is listed on
Nasdaq under the ticker symbol "GXGX." Upon closing of the business
combination (the "Business Combination"), expected to be completed
in the second quarter of 2021, shares of the combined company will
be listed on Nasdaq under the ticker symbol "CELU."
To learn more, visit www.celularity.com .
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies that are driving the next--generation of cell-based
therapies and making a meaningful difference for patients. The
Company's technology is employed by leading drug developers
worldwide, including all of the top ten global biopharmaceutical
companies. MaxCyte has granted 13 strategic platform licences to
leading cell-based therapy developers. Through 2020, MaxCyte has
granted licences for more than 140 cell therapy programmes, with
over 100 licences for clinical use. MaxCyte was founded in 1998 and
is headquartered in Gaithersburg, Maryland, US. For more
information, visit www.maxcyte.com .
About GX
GX is a blank check company incorporated in Delaware for the
purpose of effecting a merger, share exchange, asset acquisition,
share purchase, reorganization, or similar business combination
with one or more businesses or entities. GX is led by Jay R. Bloom
and Dean C. Kehler, who serve as Managing Partners of Trimaran
Capital Partners.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014, which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018.
###
Celularity Contacts
For Investors
Carlos Ramirez
Celularity Inc.
carlos.ramirez@celularity.com
Alexandra Roy
Solebury Trout
aroy@troutgroup.com
For Media
Jason Braco, Ph.D.
LifeSci Communications
+1 646 751-4361
jbraco@lifescicomms.com
GX Contact
Caroline Luz
Lambert & Co.
cluz@lambert.com
MaxCyte Contacts
MaxCyte Inc. + 1 301 944 1660
Doug Doerfler, President and Chief Executive Officer
Amanda Murphy, Chief Financial Officer
Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
Joint Corporate Broker
Numis Securities Limited +44 (0)20 7260 1000
James Black / Duncan Monteith / Matthew O'Dowd
Joint Corporate Broker
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
Financial PR Adviser + 44 (0)203 709 5700
Consilium Strategic Communications
maxcyte@consilium--comms.com
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRAIMFTMTTTBFB
(END) Dow Jones Newswires
May 25, 2021 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024